Viking soars on early-stage weight loss data as it maps out PhII

Viking Therapeutics will enter the next phase of the GLP-1 weight loss race, as the small biotech touted early data showing its investigational drug led to a drop of as much as 6% more body weight than a placebo.

With research still in the beginning stages of human testing, Viking’s…